{"id":"W4292731103","doi":"10.2337/dc22-0382","title":"Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial","year":2022,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Janssen Pharmaceuticals; Janssen Research and Development; Merck Sharp and Dohme; St. Jude Medical; Genentech; Idorsia Pharmaceuticals; Duke Clinical Research Institute; Eisai; Hebrew University of Jerusalem; Daiichi-Sankyo; Deutsche Forschungsgemeinschaft; University of Liverpool; Bayer HealthCare; Zora Biosciences; Belvoir Media Group; HLS Therapeutics; GlaxoSmithKline; IFM Therapeutics; Allergan; AstraZeneca; Amarin Corporation; Regado Biosciences; Medicines Company; American Heart Association; Intarcia Therapeutics; Ironwood Pharmaceuticals, Incorporated; Regeneron Pharmaceuticals; Brigham and Women's Hospital; Boston VA Research Institute; Boston Scientific Corporation; Novo Nordisk; MyoKardia; Daiichi Sankyo Europe; Servier; Gilead Sciences; Bristol-Myers Squibb; Cleveland Clinic; CSL Behring; Eli Lilly and Company; Moderna; Pfizer; Amgen; Sanofi; Esperion Therapeutics; Alnylam Pharmaceuticals; U.S. Department of Veterans Affairs","keywords":"Medicine; Dapagliflozin; TIMI; Type 2 diabetes; Post-hoc analysis; Diabetes mellitus; Post hoc; Kidney disease; Internal medicine; Endocrinology; Myocardial infarction","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006107427,0.002340965,0.004830201,0.0003449189,0.0003248565,0.001675265,0.0006911653,0.0009361231,0.00659079],"category_scores_gemma":[0.005386721,0.0005995227,0.006311035,0.0004410437,0.0004556735,0.0009270073,0.0007167571,0.002463688,0.0006711975],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004641692,"about_ca_system_score_gemma":0.0009592697,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007263736,"about_ca_topic_score_gemma":0.001591913,"domain_scores_codex":[0.9976287,0.001468945,0.0001644564,0.0003381312,0.0001542831,0.0002455078],"domain_scores_gemma":[0.9968739,0.00152877,0.0005900665,0.0004323751,0.0002135763,0.0003613737],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.9647499,0.001056437,0.003938435,0.0008352152,0.01535927,0.00007115803,0.00003532698,0.0009201533,0.0009662151,0.0001248983,0.003195163,0.00874771],"study_design_scores_gemma":[0.8609492,0.04868994,0.04110863,0.0001580555,0.04101075,0.0001101769,0.00006828331,0.002992604,0.001172308,0.0006964818,0.002969098,0.00007452172],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9686188,0.01151956,0.002092189,0.001252055,0.00123112,0.001839535,0.008972284,0.0002002545,0.004274213],"genre_scores_gemma":[0.9815808,0.002237869,0.001509757,0.0009323294,0.001102008,0.00228204,0.007176248,0.00007495441,0.00310405],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00659079,"threshold_uncertainty_score":0.03229958,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01387560533012188,"score_gpt":0.2528839134357027,"score_spread":0.2390083081055808,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}